CBYL Insider Trading Activity and SEC Form 4 Filings
CBYL insider trading summary
No open-market insider purchases or sales of Carbylan Therapeutics, Inc. (CBYL) have been reported on SEC Form 4 in the past 12 months.
Latest CBYL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 30, 2015 | David Renzi | President & CEO | Sell | $37K (10,000 @ $3.70) |
| Apr 14, 2015 | Acmp IV LLC | 10% Owner | Buy | $4.4M (877,500 @ $5.00) |
| Apr 14, 2015 | Albert Cha | Director | Buy | $5.0M (1,005,136 @ $5.00) |
| Apr 14, 2015 | Daniel Janney | 10% Owner | Buy | $4.4M (877,500 @ $5.00) |
| Apr 14, 2015 | Albert Cha | Director | Buy | $37K (7,364 @ $5.00) |
| Apr 14, 2015 | InterWest Partners IX, LP | 10% Owner | Buy | $4.0M (810,000 @ $5.00) |
| Apr 14, 2015 | Acp IV, L.P. | 10% Owner | Buy | $4.4M (877,500 @ $5.00) |
| Apr 14, 2015 | InterWest Management Partners IX, LLC | 10% Owner | Buy | $4.0M (810,000 @ $5.00) |
| Apr 14, 2015 | Philip T Gianos | 10% Owner | Buy | $4.0M (810,000 @ $5.00) |
| Apr 14, 2015 | Guy P Nohra | Director | Buy | $4.4M (877,500 @ $5.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.